Suppr超能文献

体外暴露于不断增加的米卡芬净浓度很容易促进光滑念珠菌分离株对棘白菌素产生耐药性。

In Vitro Exposure to Increasing Micafungin Concentrations Easily Promotes Echinocandin Resistance in Candida glabrata Isolates.

作者信息

Bordallo-Cardona María Ángeles, Escribano Pilar, de la Pedrosa Elia Gómez G, Marcos-Zambrano Laura Judith, Cantón Rafael, Bouza Emilio, Guinea Jesús

机构信息

Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain.

Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.

出版信息

Antimicrob Agents Chemother. 2017 Jan 24;61(2). doi: 10.1128/AAC.01542-16. Print 2017 Feb.

Abstract

We assessed the in vitro susceptibility of five echinocandin-susceptible Candida glabrata isolates after exposure to micafungin. The direct exposure to plates at different micafungin concentrations resulted in the inhibition of growth at 0.062 μg/ml. The progressive exposure was performed on plates using 0.031 μg/ml of micafungin and sequential propagation on plates containing the next 2-fold concentration; the MICs of micafungin and anidulafungin increased sequentially, and all the isolates became echinocandin resistant, showing fks2 mutations.

摘要

我们评估了五株对棘白菌素敏感的光滑念珠菌分离株在接触米卡芬净后的体外敏感性。将不同米卡芬净浓度直接接种于平板导致在0.062μg/ml时生长受到抑制。采用逐步接触法,在平板上使用0.031μg/ml的米卡芬净,并在含有下一个2倍浓度的平板上连续传代培养;米卡芬净和阿尼芬净的最低抑菌浓度依次增加,所有分离株均对棘白菌素耐药,显示出fks2突变。

相似文献

1
In Vitro Exposure to Increasing Micafungin Concentrations Easily Promotes Echinocandin Resistance in Candida glabrata Isolates.
Antimicrob Agents Chemother. 2017 Jan 24;61(2). doi: 10.1128/AAC.01542-16. Print 2017 Feb.
2
Spontaneous Mutational Frequency and Mutation Rates Vary by Echinocandin Agent against .
Antimicrob Agents Chemother. 2018 Dec 21;63(1). doi: 10.1128/AAC.01692-18. Print 2019 Jan.
4
FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia.
Clin Infect Dis. 2014 Sep 15;59(6):819-25. doi: 10.1093/cid/ciu407. Epub 2014 May 30.
6
FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance.
Antimicrob Agents Chemother. 2010 Dec;54(12):5042-7. doi: 10.1128/AAC.00836-10. Epub 2010 Sep 13.
7
Detection of Echinocandin-Resistant in Blood Cultures Spiked with Different Percentages of Mutants.
Antimicrob Agents Chemother. 2019 Feb 26;63(3). doi: 10.1128/AAC.02004-18. Print 2019 Mar.
8
Role of FKS Mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance.
Antimicrob Agents Chemother. 2014 Aug;58(8):4690-6. doi: 10.1128/AAC.03255-14. Epub 2014 Jun 2.
9
Rate of FKS Mutations among Consecutive Candida Isolates Causing Bloodstream Infection.
Antimicrob Agents Chemother. 2015 Dec;59(12):7465-70. doi: 10.1128/AAC.01973-15. Epub 2015 Sep 21.
10
Breakthrough invasive candidiasis in patients on micafungin.
J Clin Microbiol. 2010 Jul;48(7):2373-80. doi: 10.1128/JCM.02390-09. Epub 2010 Apr 26.

引用本文的文献

1
Mechanisms of multidrug resistance caused by an Ipi1 mutation in the fungal pathogen Candida glabrata.
Nat Commun. 2025 Jan 25;16(1):1023. doi: 10.1038/s41467-025-56269-z.
2
Unlocking the potential of experimental evolution to study drug resistance in pathogenic fungi.
NPJ Antimicrob Resist. 2024 Dec 12;2(1):48. doi: 10.1038/s44259-024-00064-1.
3
Antifungal susceptibility, molecular epidemiology, and clinical risk factors of in intensive care unit in a Chinese Tertiary Hospital.
Front Cell Infect Microbiol. 2024 Oct 7;14:1455145. doi: 10.3389/fcimb.2024.1455145. eCollection 2024.
5
Risk Factors and Clinical Characteristics of Patients with Ocular Candidiasis.
J Fungi (Basel). 2022 May 11;8(5):497. doi: 10.3390/jof8050497.
6
Expanded Access Use of Rezafungin for Salvage Therapy of Invasive Infection: A Case Report.
Open Forum Infect Dis. 2021 Aug 28;8(11):ofab431. doi: 10.1093/ofid/ofab431. eCollection 2021 Nov.
7
A Noncanonical DNA Damage Checkpoint Response in a Major Fungal Pathogen.
mBio. 2020 Dec 15;11(6):e03044-20. doi: 10.1128/mBio.03044-20.
8
Pan-Echinocandin-Resistant Bloodstream Infection Complicating COVID-19: A Fatal Case Report.
J Fungi (Basel). 2020 Sep 6;6(3):163. doi: 10.3390/jof6030163.
9
Azole-resistant Aspergillus and Echinocandin-resistant Candida - What are the treatment options?
Curr Fungal Infect Rep. 2020 Jun;14(2):141-152. doi: 10.1007/s12281-020-00379-2. Epub 2020 Mar 26.
10
Clinical and Laboratory Development of Echinocandin Resistance in : Molecular Characterization.
Front Microbiol. 2019 Jul 11;10:1585. doi: 10.3389/fmicb.2019.01585. eCollection 2019.

本文引用的文献

2
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.
Clin Infect Dis. 2016 Feb 15;62(4):e1-50. doi: 10.1093/cid/civ933. Epub 2015 Dec 16.
3
Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis.
J Antimicrob Chemother. 2015 Oct;70(10):2854-61. doi: 10.1093/jac/dkv173. Epub 2015 Jul 14.
4
Echinocandin resistance: an emerging clinical problem?
Curr Opin Infect Dis. 2014 Dec;27(6):484-92. doi: 10.1097/QCO.0000000000000111.
5
Abdominal candidiasis is a hidden reservoir of echinocandin resistance.
Antimicrob Agents Chemother. 2014 Dec;58(12):7601-5. doi: 10.1128/AAC.04134-14. Epub 2014 Oct 6.
8
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients.
Clin Microbiol Infect. 2012 Dec;18 Suppl 7:19-37. doi: 10.1111/1469-0691.12039.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验